Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2079 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2079Here is how UBS value REGN, note NO single penny for RGC: "Valuation: $435Miljenko Zuanic-last Friday
2078REGN (Regeneration is leading developer, not Sanofi) is advancing anti-PD-1 intoMiljenko Zuanic-last Friday
2077No guesses from me, I do not know.Biotech Jim-last Thursday
2076Any guesses on what they will price it at? I think I read somewhere analysts prFelix B-last Thursday
2075How much value do you ascribe to RGC? I.e. what would it be worth as a standalonMiljenko Zuanic-last Wednesday
2074After UK early marketing approval, Le Trait facility failure were less likely, bMiljenko Zuanic-last Wednesday
2073March 29 PDUFA is crucial. About time the went after AMGN, and they better playBiotech Jim-last Wednesday This was predictable due to old IMNX soluble IL4R antagonist and laMiljenko Zuanic-last Tuesday
2071Interesting company for REGN to look at: alk.netMiljenko Zuanic-March 18
2070For (as) trading opportunity, one can sell Mar-31 REGN puts (@370/372.5) for $10Miljenko Zuanic-March 17
2069MDCO (LDL-C hypothesis) may not be right (best) approach. One should consider LpMiljenko Zuanic-March 17
2068If anybody still likes the PCSK9 approach, today could be a very nice entry for Biotech Jim-March 17
2067My prediction for Repatha CVOT was right on mark: No CV death beneMiljenko Zuanic-March 17
2066Yes, BOTOX manufacturing and formulation is art on its own,...Miljenko Zuanic-March 14
2065I was bit sarcastic...Yes, it would be a lot of work to make an Eylea FoB. But iDewDiligence_on_SI-March 14
2064I was bit sarcastic, aflibercept is bi-trap, so comp need to bio-engineer CHOP cMiljenko Zuanic-March 14
2063AGN isn't planning to embark on new FoB programs, as far as I know. They'DewDiligence_on_SI-March 14
2062Well, Saunders can promote AGN as much as he can , but REGN has head-up with IntMiljenko Zuanic-March 14
2061AGN's Brent Saunders (on today's Barclays webcast) says Eylea will end uDewDiligence_on_SI-March 14
2060UK gives early green light to Sanofi eczema drug REUTERS 4:10 AM ET 3/14/2017 Biotech Jim-March 14
2059REGN2222 enrollment completed, results in 6 months. Fingers crossed. clinicaltrMiljenko Zuanic-March 13
2058At least somewhere (with Intellia) they have progress. bizjournals.comMiljenko Zuanic-March 9
2057Sanofi "dropped" Aflibercept ophthalmic indication (and kept oncology)Miljenko Zuanic-March 8
2056Very strange indeed, they had a peek at REGN data, was not impressed and then laFelix B-March 7
2055What is this SHIT? 12 min for primary Fourier presentation??? Miljenko Zuanic-March 6
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.